Lapatinib targets the intracellular ATP binding site of HER1 and HER2. Cells that express p95HER2 are sensitive to lapatinib, so Scaltriti's team tested whether it might be active in patients with ...

Probiotics contain different types of micro-organisms such as yeast (saccharomyces boulardii) and bacteria (such as lactobacillus, bifidobacterium). Micro-organisms (flora) are naturally found in ...

Last week, Zydus Lifesciences confirmed the receipt of an FDA warning letter at its Waghodia plant in Gujarat, India, marking the latest in a string of production reprimands for the Indian drugmaker.

Zydus Cadila said in a statement. The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a generic version of Arranon injection.

50 mg and 75 mg, Zydus Cadila said in a BSE filing. The company has received the approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 30mg, 60mg and 90 ...

is for Theophylline extended-release tablets of strengths 300 mg and 450 mg, Zydus Lifesciences said in a regulatory filing. Zydus Lifesciences inks licensing, supply pact with MSN for generic ...

Zydus' Saroglitazar Mg Granted DCGI Approval as First-Ever Treatment for NASH and NAFLD in India Saroglitazar Mg, is an innovative drug from Zydus approved by the DCGI to treat chronic liver ...

I woke up from a very long dream and I also woke up from having lost 250 pounds off of my body.” He continued by saying, “Yet, just yesterday, people were calling me fat and sick and boring ...

6 revealing a slimmer appearance from his previous posting, shared in February, that he attributed to a loss of 250 pounds. But while the time that elapsed in between his videos suggested this ...

The approval by the US Food and Drug Administration (USFDA) is for Theophylline extended-release tablets of strengths 300 mg and 450 mg, Zydus Lifesciences said in a regulatory filing.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Saroglitazar Mg, is an innovative drug from Zydus approved by the DCGI to treat chronic liver diseases such as, Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH).